Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Conditions: Pancreatic Ductal Adenocarcinoma; Locally Advanced Cancer; Metastatic Cancer Interventions: Drug: FOLFIRI; Drug: OSE2101; Drug: Nivolumab Sponsors: GERCOR - Multidisciplinary Oncology Cooperative Group; OSE Immunotherapeutics; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cancer Vaccines | Pancreas | Pancreatic Cancer | Vaccines